AbClon Inc is a Korea-based company principally engaged in the development, manufacture and distribution of antibody drug. The Company developed a bio synergy antibody, a therapeutic antibody for a new mechanism that is different from conventional therapeutic agents, and is based on the YPLUS and AffiMab platforms. The company's products include AC101, AC103, AC104, AC106, AC203, AM201, AM101, AM102 and AM103. The Company distributes its products within domestic market and to overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
31/07/26	KRW 19,700.00	+14.00%	97,942
30/07/26	KRW 17,280.00	+2.73%	141,594
29/07/26	KRW 16,820.00	-9.18%	209,516
28/07/26	KRW 18,520.00	-6.28%	126,482
27/07/26	KRW 19,760.00	+0.10%	64,686

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 31/07/2026			5-day change	1st Jan Change
19,700.00 ^KRW	+14.00%		-0.20%	-53.65%

08/06	Alligator partner Henlius doses first patients in HLX22 study	FW
22/05	Alligator Bioscience comments on Henlius update for HLX22	FW

Market Cap	393B 273M 238M 221M 203M 384M 26.1B 390M 2.61B 1.02B 13B 1.03B 1B 43.58B	P/E 2024	-14.5x	P/E 2025	-43.5x
Enterprise Value	355B 247M 215M 200M 184M 347M 23.59B 352M 2.36B 925M 11.74B 928M 908M 39.37B	EV / Sales 2024	103x	EV / Sales 2025	164x
Free-Float	80.08%	Yield 2024 *	-	Yield 2025	-

08/06	Alligator partner Henlius doses first patients in HLX22 study	FW
22/05	Alligator Bioscience comments on Henlius update for HLX22	FW
23/04	Alligator partner Henlius presents preclinical data for HLX49	FW
23/04	Alligator Bioscience Announces Preclinical Data Presentation of Hlx49 Antibody?Drug Conjugate	CI
07/04	Abclon wins 396 million won order	RE
09/03	AbClon wins 778 million won order	RE
02/03	Alligator Bioscience: First Patient Dosed in Phase 2/3 Study with HLX22 in China	FW
01/10/25	AbClon Inc. announced that it expects to receive KRW 35.999952065 billion in funding from Paratus Investment Inc., Dongyu Investment Co., Ltd, Winvest Venture Capital and other investors.	CI
27/08/25	Abclon wins 309 million won order	RE
20/05/25	Abclon Wins 354 Million Won Order	RE
19/05/25	AbClon Inc To Issue 1.4 Million Common Shares	RE
19/05/25	AbClon Inc. announced that it has received KRW 12.2122 billion in funding from Chong Kun Dang Pharmaceutical Corp.	CI
15/05/25	Abclon Wins 307 Million Won Order	RE

08/06	Alligator Bioscience comments on Henlius update on global phase 3 trial with HLX22	AQ
22/05	Alligator Bioscience comments on Henlius update on long-term follow-up data for HLX22	AQ
23/04	Alligator Bioscience comments on Henlius presentation of HLX49 preclinical data at AACR 2026	AQ
02/03	Alligator Bioscience comments on Henlius dosing first patient in Phase 2/3 breast cancer study of HLX22	AQ
04/12/24	Alligator Announces First Patient Dosed in Shanghai Henlius Biotech, Inc. Phase 3 Clinical Trial	AQ

AbClon Inc. Stock

Stocks

A174900

KR7174900001

Pharmaceuticals

Valuation: AbClon Inc.

Chart: AbClon Inc.

Latest news : AbClon Inc.

Press Releases: AbClon Inc.

Quotes and Performance

Course Extremes

Managers and Directors: AbClon Inc.

Biopharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+14.00%
1 week	-0.20%
1 month	-29.14%
3 months	-59.92%
6 months	-68.88%
Current year	-53.65%

1 week	16,250	20,450
1 month	16,250	28,350
Current year	16,250	95,800
1 year	9,770	95,800
3 years	6,810	95,800
5 years	6,810	95,800
10 years	6,810	95,800

Manager	Title	Age	Since
Jong-Seo Lee CEO	Chief Executive Officer	63	25/06/2010
Doo-Hun Kim DFI	Director of Finance/CFO	59	28/03/2024
Jong-Hoon Kim CTO	Chief Tech/Sci/R&D Officer	57	29/03/2023

Director	Title	Age	Since
Jong-Seo Lee BRD	Director/Board Member	63	-
Jung-Ho Kim BRD	Director/Board Member	62	29/03/2021
Jong-Hoon Kim BRD	Director/Board Member	57	29/03/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABCLON INC.	+14.00%	-0.20%	+73.87%	+22.36%	273M
REGENERON PHARMACEUTICALS, INC.	+3.29%	+16.25%	+39.81%	+2.79%	76.15B
SAMSUNG BIOLOGICS CO.,LTD.	-2.75%	+48.50%	+48.50%	+48.50%	47.83B
UCB	+2.72%	-9.39%	+17.04%	+176.83%	48.89B
CSL LIMITED	-3.81%	+7.74%	-54.57%	-54.17%	41.37B
BIOGEN INC.	-2.40%	+0.38%	+58.55%	-24.89%	29.99B
INCYTE CORPORATION	-2.82%	+1.57%	+59.59%	+87.57%	24.23B
MODERNA, INC.	-5.35%	+1.39%	+85.45%	-53.41%	21.75B
INNOVENT BIOLOGICS, INC.	-1.59%	-3.61%	-11.53%	+150.58%	19.25B
SWEDISH ORPHAN BIOVITRUM AB	-0.42%	+2.89%	+74.55%	+128.45%	17.14B
Average	-0.29%	+1.30%	+39.13%	+48.46%	32.69B
Weighted average by Cap.	-1.48%	+2.98%	+30.78%	+43.61%

	2024	2025
Net sales	2.34B 1.63M 1.42M 1.32M 1.21M 2.28M 155M 2.32M 15.53M 6.09M 77.36M 6.11M 5.98M 259M	4.71B 3.28M 2.85M 2.65M 2.44M 4.6M 313M 4.67M 31.28M 12.28M 156M 12.32M 12.05M 523M
Net income	-16.3B -11.34M -9.86M -9.18M -8.43M -15.91M -1.08B -16.16M -108M -42.45M -539M -42.59M -41.66M -1.81B	-17.91B -12.46M -10.83M -10.08M -9.26M -17.48M -1.19B -17.75M -119M -46.63M -592M -46.79M -45.76M -1.99B
Net Debt	-4.61B -3.21M -2.79M -2.6M -2.38M -4.5M -306M -4.57M -30.6M -12.01M -152M -12.05M -11.79M -511M	-37.93B -26.39M -22.94M -21.35M -19.6M -37.02M -2.52B -37.59M -252M -98.77M -1.25B -99.09M -96.92M -4.2B